interesting stuff, seems to be protective using receptor and anti cancer RAS inhibitor mechanism.
No expert but although a currently approved product it’s for blood pressure control, to be used for cancer and in combo with dox would require trials, so being first to market is relevant. Off-label use wouldn’t be a feasible strategy.
RAS inhibitor may be selective and promising anti-cancer in certain cancer indications, you can see the two groups below one performing well and group B (perhaps not impacted by RAS) which was underwhelming anti-cancer and x100 dose of Bisantrene.
Included Bisantrene as a comparative, note the IC50
dosing.
http://dx.doi.org/10.1177/1470320319851310
Cardioprotection thread, page-687
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.84 |
Change
0.050(2.80%) |
Mkt cap ! $309.3M | |||
| Open | High | Low | Value | Volume |
| $1.80 | $1.84 | $1.80 | $83.34K | 45.69K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1080 | $1.82 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.84 | 800 | 1 |
View Market Depth
| Last trade - 11.19am 01/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |